30Nov 2023
FDA Investigates Serious Cancer Risk Linked to CAR-T Therapies

FDA Investigates Serious Cancer Risk Linked to CAR-T Therapies

The FDA investigates a "serious risk" of patients developing new cancers after CAR-T therapy. The agency has received reports of T-cell malignancies, including CAR-positive lymphoma, leading to hospitalization or death. The risk applies to all approved CAR-T therapies, with potential regulatory action pending. CD19 CAR-Ts like Yescarta, Tecartus, Kymriah, and Breyanzi are affected. While companies like Gilead, Novartis, and BMS express confidence in their therapies' safety profiles, the FDA's inquiry raises concerns about developing secondary malignancies in patients receiving CAR-T treatments.

  • #oncology

Like

Save

Share